EryDel Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 26

Employees

  • Latest Deal Type
  • M&A

  • Investors
  • 1

EryDel General Information

Description

Developer of a non-invasive medical device and therapies designed to facilitate blood processing at the point of care. The company automates the process by handling the blood, drug, and processing systems, and its therapy is based on the unique properties of the erythrocytes to be reversibly opened under hypotonic conditions without losing their functionalities, enabling healthcare professionals to efficiently treat other rare diseases.

Contact Information

Website
www.erydel.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • Via A. Meucci, 3
  • Bresso
  • 20091 Milan(Lombardia)
  • Italy
Primary Industry
Drug Delivery
Other Industries
Other Healthcare Services
Other Healthcare Technology Systems
Acquirer
Ayma Therapeutics
Vertical(s)
Corporate Office
  • Via A. Meucci, 3
  • Bresso
  • 20091 Milan(Lombardia)
  • Italy

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

EryDel Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 08-Sep-2026 Completed Generating Revenue
6. Merger/Acquisition 20-Oct-2023 Completed Generating Revenue
5. Later Stage VC 24-Apr-2018 Completed Generating Revenue
4. Grant 07-Jan-2016 Completed Generating Revenue
3. Later Stage VC (Series B) 11-May-2015 Completed Generating Revenue
2. Early Stage VC (Series A) 03-Sep-2008 $3.7M $3.7M Completed Startup
1. University Spin-Out 01-Jan-2007 Completed Startup
To view EryDel’s complete valuation and funding history, request access »

EryDel Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a non-invasive medical device and therapies designed to facilitate blood processing at the point of care. T
Drug Delivery
Milan, Italy
26 As of 2023

Deerfield, IL
 

Hackettstown, NJ
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

EryDel Competitors (9)

One of EryDel’s 9 competitors is Baxter International, a Corporation company based in Deerfield, IL.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Baxter International Corporation Deerfield, IL
Flowonix Formerly VC-backed Hackettstown, NJ
Alzheon Venture Capital-Backed Framingham, MA
Spark Therapeutics Formerly VC-backed Philadelphia, PA
Recombinetics Venture Capital-Backed New Brighton, MN
You’re viewing 5 of 9 competitors. Get the full list »

EryDel Patents

EryDel Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3219808-A1 Engineering new metabolic pathways in isolated cells for the degradation of guanidinoacetic acid and simultaneous production of creatine Pending 27-May-2021
WO-2022248975-A1 Engineering new metabolic pathways in isolated cells for the degradation of guanidinoacetic acid and simultaneous production of creatine Inactive 27-May-2021
CA-2974181-A1 Method of evaluating the response of ataxia telangiectasia patients to glucocorticoids treatment Active 19-Jan-2015
CA-2974181-C Method of evaluating the response of ataxia telangiectasia patients to glucocorticoids treatment Active 19-Jan-2015
EP-3247805-A1 Method of evaluating the response of ataxia telangiectasia patients to glucocorticoids treatment Active 19-Jan-2015 C12Q1/6883
To view EryDel’s complete patent history, request access »

EryDel Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

EryDel Former Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Focus Gestioni Venture Capital Minority
Genextra Venture Capital Minority
Horizon 2020 Government
IRulya Therapeutics Corporation Majority
Innogest Capital Venture Capital Minority
You’re viewing 5 of 6 investors. Get the full list »

EryDel FAQs

  • When was EryDel founded?

    EryDel was founded in 2007.

  • Where is EryDel headquartered?

    EryDel is headquartered in Milan, Italy.

  • What is the size of EryDel?

    EryDel has 26 total employees.

  • What industry is EryDel in?

    EryDel’s primary industry is Drug Delivery.

  • Is EryDel a private or public company?

    EryDel is a Private company.

  • What is EryDel’s current revenue?

    The current revenue for EryDel is .

  • How much funding has EryDel raised over time?

    EryDel has raised $64.2M.

  • Who are EryDel’s investors?

    Focus Gestioni, Genextra, Horizon 2020, IRulya Therapeutics, and Innogest Capital are 5 of 6 investors who have invested in EryDel.

  • Who are EryDel’s competitors?

    Baxter International, Flowonix, Alzheon, Spark Therapeutics, and Recombinetics are some of the 9 competitors of EryDel.

  • When was EryDel acquired?

    EryDel was acquired on 08-Sep-2026.

  • Who acquired EryDel?

    EryDel was acquired by Ayma Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process